IDEAYA Biosciences (IDYA) reported a Q4 net loss Thursday of $1.49 per diluted share, compared with a loss of $0.52 a year earlier.
Analysts polled by FactSet expected a loss of $0.64.
Collaboration revenue for the quarter ended Dec. 31, 2024, was $7 million, up from $3.92 million a year earlier.
Analysts surveyed by FactSet expected $5.1 million.
The company said it had cash, cash equivalents, and marketable securities of $1.08 billion as of Dec. 31, 2024, compared with $632.6 million a year earlier, sufficient to fund operations until 2028.
The company's shares were up almost 4% in recent Thursday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。